AMD: First Quarter Analyst Consensus Estimates

Advanced Micro Devices (NASDAQ: AMD) will be reporting their first quarter financial results on April 27th after market close. Analysts have a consensus $102.50 12-month price target on the company, via a total of 39 analysts, with six analysts having strong buy ratings. 18 analysts meanwhile have buy ratings, 13 have hold ratings, 1 analyst has a sell rating and 1 has a strong sell rating on the company. The street high comes from Elazar Advisors with a $161.90 price target, and the lowest target sits at $59 from Clevelland Research.

29 analysts have revenue estimates for the first quarter. The mean revenue estimate between all 29 analysts is $3.22 billion; this number has been revised upwards from $2.73 billion at the start of the year. The highest revenue estimate is $3.3 billion, while the lowest is $3.1 billion.

Onto EBITDA estimates, there are currently only 8 analysts who have first-quarter EBITDA estimates. The mean is currently $718.9 million, with this number having been revised upwards from $519.11 million at the start of the year. The street high estimate currently sits at $739.2 million in EBITDA and the lowest is $651.5 million.

Analysts estimate that quarterly earnings per share will come in at $0.45, with this number being slightly revised upwards from $0.35 at the start of the year. Street high is $0.48 and the lowest estimate is $0.35 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Canadian Gold Drills 19.5 g/t Gold Over 1.0 Metre At Lac Arsenault

Canadian Copper Secures Key Approval for Caribou Complex Acquisition

Related News

BMO Raises Jazz Pharmaceuticals Price Target To US$205

It was announced last week wednesday that Jazz Pharmaceuticals (NASDAQ: JAZZ) would be acquiring GW...

Monday, February 8, 2021, 10:40:00 AM

Haywood Drops Cresco Labs Price Target To $24.50

Cresco Labs (CSE: CL) reported its first-quarter financial results this past week. The company announced...

Monday, May 31, 2021, 11:40:00 AM

Block: Canaccord Cuts Target To $150 Amid Market Downturn

Earlier this week Canaccord Genuity Capital Markets’ slashed their 12-month price target on Block Inc...

Friday, July 22, 2022, 04:23:00 PM

Equinox Gold: Analysts Reiterate Targets Following Pilar Mine Sale

On April 19th, Equinox Gold Corp. (TSX: EQX) announced that they sold their Pilar Gold...

Thursday, April 22, 2021, 02:39:00 PM

Organigram: Canaccord Lowers Price Target To $2.50

Yesterday, Organigram Holdings (TSX: OGI) (NASDAQ: OGI) reported their fourth quarter financials. The company announced...

Tuesday, December 1, 2020, 11:17:00 AM